scholarly journals Redefining Hormone Sensitive Disease in Advanced Prostate Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Xiaoyu Hou ◽  
Thomas W. Flaig
Keyword(s):  
Prostate Cancer ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
The United States ◽  
Castration Resistant ◽  
Hormonal Resistance ◽  
Hormone Sensitive ◽  
Hormone Resistant Prostate Cancer ◽  
Term Management

Prostate cancer is the most common cancer among men in the United States. For decades, the cornerstone of medical treatment for advanced prostate cancer has been hormonal therapy, intended to lower testosterone levels, known as Androgen Deprivation Therapy (ADT). The development of hormone-resistant prostate cancer (now termed castration-resistant prostate cancer:CRPC) remains the key roadblock in successful long-term management of prostate cancer. New advancements in medical therapy for prostate cancer have added to the hormonal therapy armamentarium. These new therapeutic agents not only provide a survival benefit but also show potential for reversing hormonal resistance in metastatic CRPC, and thus redefining hormonally sensitive disease.

scholarly journals Prostate Cancer Management During the COVID-19 Pandemic

2020 ◽  
Vol 5 (S1) ◽  
pp. 231-233
Author(s):  
Kunhi Parambath Haresh ◽  
Yousra Izzudeen ◽  
Devangana Bora ◽  
Subhash Gupta ◽  
Goura Kishor Rath
Keyword(s):  
Prostate Cancer ◽  
Hormonal Therapy ◽  
Specific Treatment ◽  
Cell Types ◽  
Response To Treatment ◽  
Cancer Management ◽  
Castration Resistant ◽  
Hormone Sensitive ◽  
Prompt Attention ◽  
Prostate Cancer Management

The COVID-19 pandemic has derailed the management of many cancers. Prostate cancer although a disease known for good response to treatment has posed unique challenges in this pandemic in view of the co-morbidities associated with these elderly patients. A pandemic specific treatment approach following the RADS (Remote, Avoid, Defer, Shorten) principle is required while dealing with these patients. Very low, low and favourable intermediate risk cancers may be kept on active surveillance rather than active treatment. Unfavourable intermediate, high and very high risk cases may follow the ‘defer’ policy by initiating hormonal therapy for 6-8 months to defer radiotherapy. When radiation is planned for these patients extreme or moderate hypo fractionation may be used to follow the ‘shorten’ policy. Metastatic hormone sensitive cancers may be initiated on hormonal therapy avoiding antiandrogens like Abiraterone and chemotherapy upfront. In the castration resistant phase the antiandrogens like Abiraterone or Enzalutamide may be given preference over chemotherapy. In the post operative settings early salvage may be preferred over adjuvant that too, using hypofractionation. Symptomatic patients require prompt attention and radiation should not be delayed for palliation of impending spinal compression or fracture or for local symptoms. Aggressive histologies like small cell types also need prompt treatment. Other general measures like universal masking, hand hygiene, physical distancing, respiratory etiquettes, etc., must also be emphasised keeping in mind the vulnerability of these patients.

scholarly journals Discovery of primary prostate cancer biomarkers using cross cancer learning

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kaiyue Zhou ◽  
Suzan Arslanturk ◽  
Douglas B. Craig ◽  
Elisabeth Heath ◽  
Sorin Draghici
Keyword(s):  
Prostate Cancer ◽  
Treatment Options ◽  
Cancer Genes ◽  
Cancer Disease ◽  
Castration Resistant ◽  
Primary Prostate Cancer ◽  
Study Population ◽  
Novel Biomarkers ◽  
Hormone Sensitive

AbstractProstate cancer (PCa), the second leading cause of cancer death in American men, is a relatively slow-growing malignancy with multiple early treatment options. Yet, a significant number of low-risk PCa patients are over-diagnosed and over-treated with significant and long-term quality of life effects. Further, there is ever increasing evidence of metastasis and higher mortality when hormone-sensitive or castration-resistant PCa tumors are treated indistinctively. Hence, the critical need is to discover clinically-relevant and actionable PCa biomarkers by better understanding the biology of PCa. In this paper, we have discovered novel biomarkers of PCa tumors through cross-cancer learning by leveraging the pathological and molecular similarities in the DNA repair pathways of ovarian, prostate, and breast cancer tumors. Cross-cancer disease learning enriches the study population and identifies genetic/phenotypic commonalities that are important across diseases with pathological and molecular similarities. Our results show that ADIRF, SLC2A5, C3orf86, HSPA1B are among the most significant PCa biomarkers, while MTRNR2L1, EEPD1, TEPP and VN1R2 are jointly important biomarkers across prostate, breast and ovarian cancers. Our validation results have further shown that the discovered biomarkers can predict the disease state better than any randomly selected subset of differentially expressed prostate cancer genes.

Modern Chemotherapy Strategies for Management of ‘Hormone Resistant Prostate Cancer’ (HRPC)—When Should the Urologist Refer?

2009 ◽  
Vol 2 (3) ◽  
pp. 92-99 ◽  
Author(s):  
Raj A. Persad ◽  
Amit Bahl
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Phase I ◽  
Phase Ii ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Phase Ii Trials ◽  
Pass Through ◽  
Hormone Resistant Prostate Cancer

Before death occurs from advanced prostate cancer, all patients pass through a ‘hormone resistant’ phase of the disease (HRPC). A large proportion of patients with advanced prostate cancer on hormonal therapy are managed in the Urology Outpatient Department, albeit with multidisciplinary input into their care. Chemotherapy for HRPC has now been shown to increase survival and quality of life and many novel agents are now undergoing Phase I and Phase II trials. The timely and appropriate referral of patients for chemotherapy, however, is essential in order to optimise patients' care and use chemotherapy wisely. This article addresses many of these practical issues.

scholarly journals Recent trends in the management of advanced prostate cancer

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1513 ◽  
Author(s):  
Chad Ritch ◽  
Michael Cookson
Keyword(s):  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Wide Spectrum ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Castration Resistant ◽  
Significant Survival ◽  
Hormone Sensitive ◽  
Recent Trends

Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or abiraterone acetate to ADT results in significant survival advantage as compared with ADT alone. Furthermore, in non-metastatic castration-resistant prostate cancer (M0 CRPC), two second-generation anti-androgens, apalutamide and enzalutamide, when used in combination with ADT, have demonstrated a significant benefit in metastasis-free survival. Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document